Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Clinical Efficacy And Safety Of Nivolumab: Results Of A Multicenter, Open-label, Single-arm, Japanese Phase II Study In Malignant Pleural Mesothelioma (MERIT)

M. Okada, T. Kijima, K. Aoe, T. Kato, N. Fujimoto, K. Nakagawa, Y. Takeda, T. Hida, K. Kanai, F. Imamura, S. Oizumi, T. Takahashi, M. Takenoyama, Hiroshi Tanaka, Jun Hirano, Y. Namba, Y. Ohe
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for the treatment of advanced or metastatic MPM. Patients and Methods: Japanese patients with unresectable, advanced, or metastatic MPM resistant or intolerant to ≤2 regimens of chemotherapy and ≥1 measurable lesion(s) were enrolled. Patients received nivolumab 240 mg intravenously every 2 weeks until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate by central assessment according to the Modified Response Evaluation Criteria in Solid Tumors. Adverse events (AEs) and treatment-related AEs (TRAEs) were evaluated. Results: Thirty-four patients were enrolled between July 2016 and October 2016. Median follow-up was 16.8 (range: 1.8–20.2) months. Ten (29%, 95% confidence interval, 16.8–46.2) patients showed a centrally assessed objective response. The objective response rates were 26% (7/27), 67% (2/3), and 25% (1/4) patients for epithelioid, sarcomatoid, and biphasic histologic subtypes, respectively. Median duration of response was 11.1 months with a 68% disease control rate. Median overall survival and progression-free survival were 17.3 and 6.1 months, respectively. The objective response rate was 40% with programmed death-ligand 1 expression ≥1% and 8% with <1%. Thirty-two patients (94%) experienced AEs and 26 (76%) experienced TRAEs. Conclusions: Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity. See related commentary by Mansfield and Zauderer, p. 5438
This paper references
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma
B Castagneto (2008)
Annual trend of the number of deaths due to mesothelioma by prefecture (1995 to 2016) Population dynamics statistics by the Ministry of Health
Ministry Of Health
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
Highlights of prescribing information: opdivo (nivolumab), for intravenous use
Bristol-Myers Squibb
10.2486/INDHEALTH.MS1184
Future trends of mesothelioma mortality in Japan based on a risk function.
Tomoya Myojin (2012)
PD-L1 expression in malignant mesothelioma: an immunohistochemical analysis of 33 cases
ML Cowan (2014)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1111/j.1349-7006.2011.02165.x
National survey of malignant mesothelioma and asbestos exposure in Japan
K. Gemba (2012)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.2482/HAIGAN.52.371
A Clinical Study of 34 Malignant Pleural Mesothelioma Patients Treated with Pemetrexed from Nagasaki Thoracic Oncology Group
Takaya Ikeda (2012)
NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY
D. Agnese (2020)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1111/ajco.12788
PD‐L1 expression associated with worse survival outcome in malignant pleural mesothelioma
B. Nguyen (2018)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.3109/0284186X.2012.709948
Treatment and survival analyses of malignant mesothelioma in Japan
K. Gemba (2013)
Guidelines in Oncology: Malignant Pleural Mesothelioma
NCCN Clinical Practic (2018)
10.1016/j.jtho.2017.09.1968
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
N. S. Patil (2018)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Prognostic significance ofmetabolic response bypositron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma
Y Tsutani (2013)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.21037/atm.2017.06.26
Malignant pleural mesothelioma: predictors and staging.
W. Richards (2017)
10.1016/j.jtho.2018.05.038
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
J. Quispel-Janssen (2018)
Annual trend of the number of deaths due to mesothelioma by prefecture (1995 to 2016) Population dynamics statistics by the Ministry of Health, Labour and Welfare
Health (2016)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1093/annonc/mds537
Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
Y. Tsutani (2013)
10.1097/JTO.0b013e31817c73d6
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)



This paper is referenced by
Immune checkpoint inhibition : chemotherapy-free regimens & new PD-1 inhibitors on the horizon S 117 Early-stage lung cancer
A. A. Adjei (2020)
10.21037/JXYM-20-79
Biomarkers in the diagnosis and treatment of malignant pleural disease: an integrative review
F. Buttitta (2020)
Immunotherapy for mesothelioma: rationale and new approaches.
Joshua E Reuss (2020)
10.1016/s1470-2045(19)30642-4
Tumour Treating Fields for mesothelioma: controversy versus opportunity.
D. Fennell (2019)
10.1080/17476348.2019.1679119
Types of surgery post-neoadjuvant chemotherapy for pleural mesothelioma
K. Kuribayashi (2019)
10.1038/s41571-019-0291-4
Immunotherapy trials in mesothelioma — promising results, but don’t stop here
A. Nowak (2019)
10.21873/anticanres.14140
Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells
T. Shukuya (2020)
10.3389/fonc.2020.00187
Immunotherapy in Malignant Pleural Mesothelioma
C. J. de Gooijer (2020)
10.3390/cancers12123846
Establishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
R. Affatato (2020)
10.1016/j.coi.2020.04.005
Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma.
S. Mutsaers (2020)
10.1007/s12094-019-02275-9
Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
S. Cedres (2020)
10.3389/fonc.2020.00777
Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
Robert A. Belderbos (2020)
10.21037/tlcr-19-425
SMO mutations confer poor prognosis in malignant pleural mesothelioma.
D. Signorelli (2020)
10.3390/cancers12092557
Treatment of Metastatic Uveal Melanoma: Systematic Review
Cristina Rodriguez-Vidal (2020)
10.5772/intechopen.89116
Immunocheckpoint Blockade in Malignant Pleural Mesothelioma
N. Fujimoto (2019)
10.1080/14712598.2020.1703945
Nivolumab for the treatment of unresectable pleural mesothelioma
K. Hotta (2019)
10.1136/bcr-2020-237721
Nivolumab for malignant peritoneal mesothelioma
Takaaki Tanaka (2020)
10.1016/j.jtho.2020.03.006
Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.
J. Remon (2020)
10.21037/tlcr.2020.01.16
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesothelioma.
M. Disselhorst (2020)
10.1016/j.ebiom.2020.103040
Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
Joanne M Mankor (2020)
10.1016/j.ebiom.2020.103057
An appropriate choice for immunotherapy in malignant pleural mesothelioma
N. Fujimoto (2020)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
10.1093/jjco/hyaa069
Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma.
Akifumi Nakamura (2020)
10.1158/1078-0432.CCR-20-1767
Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Runzhe Chen (2020)
10.1002/rcr2.536
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
K. Tsubouchi (2020)
10.1158/1078-0432.CCR-19-1836
Nivo-lution in Mesothelioma
A. Mansfield (2019)
10.1016/j.lungcan.2020.05.023
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
K. Otsuka (2020)
10.5603/ARM.a2020.0103
New horizons from novel therapies in malignant pleural mesothelioma.
M. Sayan (2020)
10.1016/j.jtocrr.2020.100093
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms
P. Szlosarek (2020)
10.1183/2312508x.10024219
Mesothelioma: is chemotherapy alone a thing of the past?
A. Bibby (2020)
10.3390/cancers12051284
Acidosis-Induced TGF-β2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response
Natalia Trempolec (2020)
10.1016/j.jtocrr.2020.100075
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
Tamkin Ahmadzada (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar